Sign in Subscribe

Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach

With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.

Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
Credit: Sarepta Therapeutics
Already have an account? Sign in.